Corvus Pharmaceuticals, Inc. — Director's Dealing 2016

Mar 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2016-03-29

Reporting Person: MILLER RICHARD A MD (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-29	Common Stock, $0.0001 par value	C	266310	—	Acquired	984538	Indirect
2016-03-29	Common Stock, $0.0001 par value	C	62455	—	Acquired	1046993	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-29	Series A Preferred Stock	$	C	266310	Disposed		Common Stock (266310)	Indirect
2016-03-29	Series B Preferred Stock	$	C	62455	Disposed		Common Stock (62455)	Indirect

Footnotes

F1: The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering.

F2: A portion of these shares is subject to a right of repurchase held by the Issuer.

F3: These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the "Miller-Horning Trust"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller-Horning Trust.

F4: The expiration date is not relevant to the conversion of these securities.